3 results
Primary: To determine the efficacy of SAR442168 compared to a daily dose of 14 mgteriflunomide (Aubagio) in decreasing relapses in RMS.Secondary:1. To evaluate safety, tolerability, and efficacy of SAR442168 compared to placebo on clinical endpoints…
In oral FXa inhibitor-treated patients with acute intracerebral bleeding, the objectives of this study are as follows:Primary Efficacy Objective:To evaluate the effect of andexanet versus usual care on the rate of effective hemostasis.Secondary…
The goal of the fenebrutinib development program in MS is to evaluate the benefits and risks of fenebrutinib treatment across the spectrum of patients with MS. Based on the existing toxicology, pharmacology, and clinical experience with fenebrutinib…